NCT04691180View on ClinicalTrials.gov

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

September 16, 2021

Study Completion Date

September 16, 2021

Conditions
COVID-19
Interventions
DRUG

BRII-196 and BRII-198

BRII-196 and BRII-198 given intravenously

DRUG

Placebo

Placebo given intravenously

Trial Locations (1)

100015

Investigative Site, Beijing

Sponsors
All Listed Sponsors
collaborator

TSB Therapeutics (Beijing) CO.LTD

INDUSTRY

lead

Brii Biosciences Limited

INDUSTRY

NCT04691180 - A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 | Biotech Hunter | Biotech Hunter